ArticleBMC cardiovascular disorders2025
Serum alkaline phosphatase levels and their association with neurological outcomes post-cardiac arrest.
Article in BMC cardiovascular disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAlkaline phosphatase (ALP) has been associated with an increased risk of cardiovascular events and is strongly correlated with adverse cerebrovascular outcomes. However, the relationship between ALP and neurological outcomes post-cardiac arrest (CA) remains underexplored. This study aims to investigate the association between serum ALP levels and 3-month neurological outcomes in patients who have experienced CA.
methodsA retrospective review of 354 CA patients was conducted. Data for the study population were sourced from the DRYAD Digital Repository. Participants were categorized into three groups based on ALP level tertiles. Neurological outcomes were assessed at 3 months, with unfavorable neurological outcomes defined as a Cerebral Performance Categories (CPC) score of 3 to 5.
resultsAfter adjusting for covariates, elevated ALP levels were independently associated with an increased risk of unfavorable neurological outcomes post-CA (odds ratio = 1.095, 95%confidence interval: 1.021-1.174; P = 0.011). Compared to the low ALP tertile, the high ALP tertile exhibited a 1.54-fold increased risk of unfavorable neurological outcomes.
conclusionElevated serum ALP levels were correlated with a higher risk of suboptimal neurological outcomes within 3 months following CA.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.